{"entity":{"id":"nct07295821","kind":"trial","name":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study","aka":[],"tldr":"A phase 2 trial of Osimertinib in advanced solid tumours, run by AstraZeneca, now recruiting.","summary":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study is a phase 2 interventional study registered as NCT07295821 by AstraZeneca, with 60 participants planned, started 2026-04-01 and due to reach its primary completion in 2029-05-30. Interventions recorded: Osimertinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07295821","url":"https://clinicaltrials.gov/study/NCT07295821"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["osimertinib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07295821","phase":"2","setting":"Phase II, Single-arm Multicenter Study of Osimertinib Induction Before Radiotherapy and Maintenance in Chemo-ineligible or Refusing Patients With Stage III, Unresectable NSCLC and EGFR Mutation-positive Tumors","sponsor":"AstraZeneca","participation":[{"nct":"NCT07295821","source":"https://clinicaltrials.gov/study/NCT07295821","fetchedAt":"2026-10-07T16:55:38.126Z","studySha256":"0274a68df8f54cf7f3cca4a6d1582f2ccc1f4d716b0a9393a262d3204b4875c1","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-08","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":60,"enrolmentType":"ESTIMATED","siteCount":20,"recruitingSiteCount":2,"countries":["China"]}],"started":"2026-04-01","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07295821/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}